![Lisa Massmanian](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Lisa Massmanian
Keine laufenden Positionen mehr
Profil
Lisa Massmanian formerly worked at Curis, Inc., as Director-Clinical Operations, ImmunoGen, Inc., as Research Associate, and Merrimack Pharmaceuticals, Inc., as Manager-Clinical Operations.
Ms. Massmanian received her graduate degree from Northeastern University.
Ehemalige bekannte Positionen von Lisa Massmanian
Unternehmen | Position | Ende |
---|---|---|
MERRIMACK PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
IMMUNOGEN, INC. | Corporate Officer/Principal | - |
CURIS, INC. | Geschäftsführer | - |
Ausbildung von Lisa Massmanian
Northeastern University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CURIS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Merrimack Pharmaceuticals, Inc.
![]() Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA. | Health Technology |
ImmunoGen, Inc.
![]() ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |